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Access to quality and affordable healthcare is a worldwide problem. Making healthcare 
affordable to the ordinary South African is a priority of the national government and 
therefore the use of generic medicine is encouraged. Generic medicines are manufactured 
by pharmaceutical companies without a licence from the innovator company, and are 
expected to work physiologically in the same manner as the innovator, based on their 
bioequivalence. These medicines normally cost less than innovator medicines. One method 
of reducing the costs of healthcare is by the introduction of generic medicine for the 
treatment of non-communicable diseases. This cross-sectional retrospective study 
investigated the potential savings from the use of generic medicine for the treatment of the 
most common non-communicable diseases of adults in South Africa.   
 
Five of the most common non-communicable chronic diseases in South Africa were 
extracted from the Council for Medical Schemes chronic disease list. The innovator drug, 
along with available generic drugs, was selected and an algorithm was designed to compare 
the single exit price differences for a treatment period of 30 days. To assess the price 
changes over a period of time, the innovator and generic medicine prices were compared in 
2006 and 2014. 
 
This study has shown that there was a major saving potential from the use of generic 
medicines over innovator medicines for the treatment of the most common non-
communicable diseases in adults in South Africa. This has been proven by comparing the 





findings confirm that medicine prices between innovator and generic brands vary 
extensively. A major saving of 97.14% for furosemide, 97.11% for prednisone and 95.70% 
for glibenclamide existed when generic medicines were used. Minor savings of 8.06% for 
budesonide and 12.68% for metformin existed when generic medicines were used instead 
of the innovator product. Secondly, this study has shown that over a period of eight years, 
most generic drug prices have increased in line with the South Africa’s nominal inflation 
rate, except for the methotrexate which increased by 75.70%, while simvastatin 10mg and 
20mg generics decreased by 69.95% and 72.32% respectively. These results confirm the 
recommendations that generic medicine can be utilised effectively to ensure accessibility 
and affordable quality healthcare to all. However, constant monitoring of price changes is 
needed to ensure that above inflation increases do not erode affordability of quality 
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CHAPTER 1: INTRODUCTION 
 
The South African Constitution states that “everyone has the right to have access to 
healthcare (Act 108 of 1996).” As a result, making healthcare affordable and accessible to 
ordinary people is a major priority for the national government in South Africa (Gordhan, 
2014). Therefore, to make quality healthcare accessible, the Department of Health (DoH) 
has encouraged the use of generic medicines to ensure affordability. Generic medicines 
offer a solution to the healthcare network, allowing access to quality medicines at a cost 
affordable to many people.  
 
The World Health Organisation (WHO) defines a generic medicine as follows:  
 
“A pharmaceutical product, usually intended to be interchangeable with an 
innovator product that is manufactured without a licence from the innovator 
company and marketed after the expiry date of the patent or other exclusive 
rights. Generic drugs are marketed under a non-proprietary or approved name 
rather than a proprietary or brand name. Generic drugs are frequently as 
effective as, but much cheaper than, brand-name drugs. Because of their low 
price, generic drugs are often the only medicines that the poorest can access. A 
brand name is a name given to a drug by the manufacturer. The use of the name 
is reserved exclusively for its owner (WHO, 2014).” 
 
As described by the WHO, Colligan in 2009 stated that, generics are made of the same active 
ingredients, and are expected to work the same way in the body, they also have the same 
risks and benefits as their innovator counterparts (Colligan, 2009). These medicines are 
expected to be less expensive because manufacturers don’t have the investment costs of 
developing a new drug. As a result, each year generic medicines save consumers and the 
healthcare systems tens of billions of US dollars (Colligan, 2009). Nearly 69 per cent of all 




prescriptions in the United States (US) are filled with generic medicines, with roughly 16 
cents of every dollar spent on prescriptions, are being spent on generic medicines (Colligan, 
2009). However, generic medicines should be comparable to the innovator drug based on 
bioequivalence to achieve the same therapeutic effect (de Lira et al., 2014).   
 
The US Food and Drug Administration (FDA) defined bioequivalence as: 
“The rate and extent to which the active ingredient or active moiety is absorbed 
from a drug product and becomes available at the site of action. For drug 
products that are not intended to be absorbed into the bloodstream, 
bioavailability may be assessed by measurements intended to reflect the rate 
and extent to which the active ingredient or active moiety becomes available at 
the site of action (US Food and Drug Administration, 2011).” 
 
The US has approved the Hatch-Waxman Act in 1984, which allowed the FDA to accept the 
use of generic medicines based on bioequivalence. The purpose of this law was to increase 
affordability and accessibility of medication to the consumer, by allowing generic 
manufacturers not to subject their products for clinical trials and tests, resulting in cheaper 
production costs (Lichanda et al., 2013). Many high income countries (e.g. the US, the 
United Kingdom (UK), Switzerland), allowed generic medicines into their health systems and 
imposed generic substitution of innovator or branded medication wherever possible, to 
save costs (Lichanda et al., 2013). These medicines generally cost between 20%-90% less 
than an innovator medicine (Dunne et al., 2013). In the US, generic medicines account for 
two thirds of all prescriptions and 20% of the spending on pharmaceuticals (Lichanda et al., 
2013). 
 




Other countries all over the world also encourage the use of generic medicines to enable 
access to quality healthcare. For example, in Canada, regulators have set minimum 
standards for the acceptance of generic drugs onto the local market, these standards 
include 90% confidence intervals for the maximum peak concentration and total drug 
exposure over time, with an area under the curve limit of 0.80 to 1.25 (McCormack & 
Chmelicek, 2014). This translates into a bioequivalence difference of no more than 5% to 7% 
when compared to the innovator (McCormack & Chmelicek, 2014). 
 
In a study conducted by Olszynski et al. (2014) in Canada, the dissolution rates of innovator 
and generic forms of alendronate and risedronate were compared. The results were 
unexpected, as the two generic versions of the alendronates disintegrated faster than the 
innovator. This posed as a risk, as the drug may cause an interaction with the esophageal 
mucosa and enhance the possibility of side effects (Olszynski et al., 2014). 
 
A pilot study, which was conducted in Penang, in Malaysia, measured the extent to which 
generic substitution practices took place at community pharmacy level (Ping et al., 2008). 
This study reported that 47% of pharmacists had promoted generic substitution to their 
customers, and most of the prescribers when contacted by pharmacists accepted the 
suggestion of generic substitution. Eighty (80%) percent of consumers accepted a 
pharmacist’s recommendation to substitute their prescribed treatment with generic 
medicines (Ping et al., 2008).           
  
The prescribing patterns of doctors are influenced by many dynamics. However, the most 
influential factor is the visit from a pharmaceutical sales representative (Fugh-Berman & 




Ahari, 2007). It is projected that some 20 million visits are made by sales representatives to 
doctors and hospitals in Germany annually (Lieb & Scheurich, 2014). Fifty three percent 
(53%) of prescribers believed that the prescribing habits were influenced by incentives 
received from a sales representative be it drugs samples, stationary or dinner invitations 
(Lieb & Scheurich, 2014).    
 
In Brazil, generic drugs were introduced in 1999. Since then, the prices of medication in 
general have fallen between 40% and 62% (de Lira et al., 2014). However, the sales of 
generic medicines account for only 27.1% of the total pharmaceutical market spend analysis 
(de Lira et al., 2014), while family expenditure on medication accounts for approximately 
48.6% of total healthcare expenses. Therefore the introduction of generic medicine in Brazil 
became a good alternative for large segments of the population (de Lira et al., 2014). 
 
In another recent study, Cameron and Laing reported that an average of 9% to 89% could be 
saved by a single-medicine-switch from innovator brands to lowest-priced generic 
equivalents (Cameron & Laing, 2010). In Pakistan, it is believed an average of 51% of the 
current private sector spending could be saved across the 9 medicines studied, and the net 
savings would exceed US$ 12 million. In China a potential US$ 86 million could be saved 
from the substitution of just four medicines, while saving a patient an average of 65% 
(Cameron & Laing, 2010).  
 
In a study conducted in Europe by Simoens and De Coster, which aimed to determine the 
savings from increased substitution of generic for innovator medicines, the methodology 
used in this study was based on the potential saving from substituting a generic medicine 




for an innovator medicine. The study included ten active substances in each country within 
Europe, which had the highest public expenditure of an innovator brand in 2004. The results 
revealed that an estimated €3 billion saving for the 11 countries would be achieved by 
generic substitution (Simoens & De Coster, 2006).  
 
Literature from Shrank and colleagues (2011b) described prior research indicating that while 
patients generally have favourable views about the quality, cost and value of generic 
medicines, the majority do not prefer to use them (Shrank et al., 2011b). Although patient 
perceptions play a vital role in the selection of medication, they rarely communicate with 
their doctors about out-of-pocket costs of medication and medication choices, and this 
consequently leaves the doctor with a substantial influence over medication selection 
(Shrank et al., 2011b). To improve generic medication usage, it would be ideal to understand 
doctors’ perceptions about the quality and efficacy of generic medicines. Therefore, 
prescribers’ attitude towards the use of generic medicines could create a hurdle in the aim 
of making healthcare more affordable and accessible.  
 
In South Africa, once democracy was achieved in 1994, the governing party, i.e., the African 
National Congress, was challenged with creating a National Health Plan (NHP) for South 
Africa to make healthcare accessible and affordable. The aim was to create a system which 
is able to achieve a unitary, comprehensive, equitable and integrated national health system 
(Department of Health, 2010). The greatest test of the national government at the time, was 
not only focussed on providing quality affordable medicines for the majority of the 
population, but it also had to deal with economic injustices and to increase productivity, 
while exercising greater control of personal wellness (Yach & Kistnasamy, 2007). With the 




construction of a new health system under direction of the NHP, many programmes were 
introduced in the public sector which culminated and became known as the Reconstruction 
and Development Programme (RDP) (Kautzky & Tollman, 2008). The RDP was responsible 
for creating infrastructural development, greater access to water and electrification, 
availability of social welfare grants to the previously disadvantaged populations, and free 
maternal and child health care (Kautzky & Tollman, 2008). However, the challenge of 
affordability and accessibility of medicines is not only felt by the public healthcare sector, 
but also affects the private healthcare sector.  
 
A major problem facing the private sector is the hasty increase in spending in particular by 
those patients on medical aid schemes, medical insurances and hospital plans, as the annual 
spending increases, so do medical aid contributions (van de Merwe, 2014). Often individuals 
who belong to the medical aid schemes are struck with an above inflation increase in 
monthly contributions (van de Merwe, 2014). In an attempt to limit the increasing cost of 
private health care, some medical aid schemes have introduced a generic medicine strategy, 
whereby the scheme encourages the use of generic medicine (Sheppard & Principal, 2010). 
Usually, prescription drugs are the most expensive element of any health care plan and the 
costs generally continue to rise as drug utilisation increases, and new more expensive drugs 
are introduced into the marketplace (Manulife Financial, 2010).  
 
At the moment, the South African healthcare system is an unbalanced two-tiered system, 
i.e., the public and the private healthcare systems. However, the public healthcare sector 
delivers its services to about 80% of the population with limited resources (Ruff et al., 2011). 
To deal with the burden of providing quality healthcare, the South African government is 




currently developing a new healthcare system called the National Health Insurance (NHI). 
The NHI intends to ensure that all South Africans have access to quality healthcare (Naidoo, 
2012). The use of generic medicines is the cornerstone of providing quality and affordable 
healthcare to all South Africans through the NHI. Recent studies have shown that the 
generic drugs entering the South African market have a 20% - 30% price differential when 
compared to an innovator drug price, whereas in developed countries a cost differential of 
up to 90% is seen, due to the domination of expensive generics in the market (Bateman, 
2014). As Nicolosi and Gray (2009) stated, the South African government committed itself to 
the use of generic medicines as a key cost savings mechanism and to promote the 
availability of safe and effective drugs at the lowest possible cost. Colligan (2009) also 
reported that generic drugs represent a safe, effective, and affordable method to decrease 
overall healthcare costs to the state. More importantly, medicines are fundamentally used 
in the management of many chronic diseases. 
 
According to Bradshaw & Steyn (2001), South Africa is a middle income country that has 
amongst the most extreme inequalities in wealth in the world. The national statistics 
suggest that 52% of the households were living in poverty in 1996, although the degree of 
poverty depends on the poverty line and methodology used (Bradshaw & Steyn, 2001). With 
increasing pressure on the healthcare system, it is imperative that everyone has access to 
healthcare facilities while spending the least amount of money on prescription medication 
and having more money available for other healthcare services. Therefore, the use of 
generic medicine plays an important role in a patient’s lifestyle (Bradshaw & Steyn, 2001).  
In 2001, more than forty of the world’s largest pharmaceutical companies had made an 
attempt to stop the South African government from trying to introduce legislation aimed at 




reducing the price of medicines, and allowing the importation of cheaper drugs in South 
Africa (Sidley, 2001). A study conducted by Patel et al., to determine patients and health 
care worker’s perceptions about the quality of generic medicines available in South Africa, 
revealed that generic medicines were acceptable by patients who had chronic illnesses or 
where cost plays a key factor (Patel et al., 2012).   
    
Nicolosi and Gray (2009) obtained prices of innovator drugs and compared them to the 
prices of two generic drugs for the twenty five listed chronic conditions set out by the 
Council for Medical Schemes (CMS). Their results showed that, out of all the generic 
medicines identified, 67.5% were more than 40% cheaper, per defined daily dose per 
month, than the innovator product. They also reported that in 16 medicines the cost 
differentials between generic versions were 1% or less. Some correlation between the 
number of generics and the size of the cost differential was apparent (correlation coefficient 
0.49). There were examples of high-cost differentials in highly competitive areas of the 
market (Nicolosi & Gray, 2009).  
 
As Aikins and colleagues reported, Africa bears a significant proportion of the global burden 
of chronic diseases, along with poor countries of Asia and Latin America (Aikins et al., 2010). 
Africa's chronic disease problem is attributed due to a number of factors that include 
increased life expectancy, changing lifestyle practices, poverty, urbanisation and 
globalisation. With an increasing morbidity and mortality rate from chronic diseases, the 
result is an even greater burden of infectious disease, which accounts for at least 69% of 
deaths on the continent (Aikins et al., 2010). Most non-communicable diseases are chronic 
in nature and require treatment indefinitely. This places a huge burden on the country’s 




financial economy to ensure accessibility and availability of medicines in the primary 
healthcare system.   
 
The WHO describes non-communicable diseases (NCD) as: 
 
“chronic diseases which are not passed from person to person. They are of long 
duration and generally slow progression. The four main types of NCDs are 
cardiovascular diseases (like heart attacks and stroke), cancers, chronic 
respiratory diseases (such as chronic obstructed pulmonary disease and asthma) 
and diabetes” (World Health Organisation, 2014).  
 
The NCDs emerge over an extended period of time and are preceded by an unhealthy 
lifestyle, resulting in risk factors such as obesity, increased blood pressure, increased blood 
glucose levels, increased cholesterol levels, physical inactivity, uncontainable alcohol and 
tobacco use (Puoane et al., 2008). A South African comparative risk assessment conducted 
in 2000 identified that NCDs often advanced to mortality resulting from diseases such as 
diabetes mellitus, ischaemic heart disease, stroke and hypertensive disease (Puoane et al., 
2008). NCDs are believed to cause disruption to the labour force and productivity output of 
the country by targeting the working-age populace due to unhealthy lifestyle practices, 
which are being passed down to the youth and therefore it is critical to prevent further 
NCDs by identifying individuals at risk and assisting them in changing their behaviour 
(Bradshaw et al., 2010). 
 




Mayosi and colleagues (2009) stated that NCDs are emerging rapidly in both urban and rural 
areas and are predominantly seen in poor people and this burden is expected to increase 
significantly over the next decades to come if actions are not taken to halt this trend. With 
the increasing number of deaths from diabetes, chronic kidney disease, cancer of the cervix 
and prostate, and neuropsychiatric disorders it is noticeable that the burden of NCDs is 
rising (Mayosi et al., 2009). The WHO estimates that NCDs caused 28% of the total burden 
of disease, and that the burden is two to three times higher than in developed countries, 
with similar results seen in sub-Saharan countries (Mayosi et al., 2009). To manage the 
burden, policy amendments have been implemented to control the sale of tobacco and to 
promote the development of a responsible and sustainable liquor industry (Mayosi et al., 
2009). Large investments and development into the primary health care system are needed 
to manage the burden of NCDs, in addition, initiatives to promote good health should be a 
nationwide phenomenon starting with school sites and proceeding to community based 
institutions (Mayosi et al., 2009).  
 
According to the Medicines and Related Substances Act, 101 of 1965, the level of increase in 
the single exit price (SEP) of a medicine or scheduled substance is determined by the 
Minister of Health and based annually on “the average consumer price index for the 
preceding year; the average producer price index for the preceding year and foreign 
exchange rates” (Medicines and Related Substances Act, 1965). In a circular published by 
the CMS (2013), which evaluated the contribution increase assumptions for the year 2013, it 
was expected that medicine price would increase by 6% on average, which was in line with 
the approved SEP increase of 5.8%, and that the average cost of medicines within a private 
hospital would increase by 8.9% (Council for Medical Schemes, 2013).   




The aims of this study, therefore, were to compare the prices of the innovator and generic 
medication required for one month of treatment of a non-communicable disease and to 
assess the price changes over a period of time.  
  




CHAPTER 2: METHODOLOGY 
 
This chapter details the research methodology used to enable the objectives of this study to 
be met.  
 
2.1 Research design 
This was a cross-sectional retrospective study which assessed and compared the prices of 
medication required per month for the treatment of non-communicable diseases in South 
Africa in September 2006 and in July 2014.  
 
 2.2  Objectives  
The objectives of the study were: 
2.2.1  To assess the cost of generic and innovator medicines used to treat common non-
communicable diseases in South Africa. 
2.2.2 To compare the price differential between generic and innovator medicines in 2006 
and in 2014. 
2.2.3  To assess the potential cost savings when generic medicines are used instead of 
innovator medicines to treat common non-communicable diseases in South Africa.  
 
  





The medicines available for the treatment of each of the chosen non-communicable 
diseases were extracted from the Pharmaceutical Blue books (Pharmaceutical Blue Book. 
2006; 2014). Only medicines that were available in the Standard Treatment Guidelines, 
Primary Heath Care Level (Department of Health, 2008) were used for this study. The single 
exit price (SEP), inclusive of 14% value added tax (VAT) in the South African currency (the 
Rand), and the defined daily dose (DDD) of each medicine were used to calculate the 
monthly costs.  
 
To assess the cost differentials over time, the cost of medicines in 2006 and in 2014 were 
compared using prices listed in the Pharmaceutical Blue books (Pharmaceutical Blue Book. 
2006; 2014).  
 
The innovator drugs along with available generic drugs were selected, and an algorithm was 
designed to compare the SEP differences. The cost per DDD for a treatment period of 30 
days was used as a monthly supply of medication. The DDD is defined as, the assumed 
average maintenance dose per day for a drug used for its main indication in adults (World 
Health Organisation Collaborating Centre for Drug Statistics Methodology, 2009). The 
recommended minimum daily dosage described in the South African Medicines Formulary 
(2014) for each non-communicable disease was used, and quantity required for a month’s 
supply of medicine was calculated. Since pharmaceutical drugs are available in various 
strengths and are specific to a disease stages, the different strength prices were also 
compared where applicable.  
 




The monthly defined daily dosage (MDDD) cost (R) was calculated as follows: 
 
                            ( )  
(    )    (    )              
        
 
 
30 days = Taken as the average number of days in a month 
SEPV = Single Exit Price inclusive of VAT 
DDD / strength = Number of tablets/capsules required for DDD 
Quantity = Number of tablets/capsules in presentation at the SEP 
 
Data were then entered into a Microsoft Excel spread sheet for analysis; validation and 
proof-reading was done by the researcher to ensure accuracy. 
 
To identify the disease conditions to be investigated, a list was extracted from the CMS 
(Council for Medical Schemes, 2014) detailing the most common non-communicable chronic 
diseases in South Africa, and a shortlist was thereafter completed. The following five most 
common non-communicable chronic diseases in South Africa were chosen (Council for 
Medical Schemes, 2014):  
 
1. Hypertension 
2. Diabetes Mellitus Type 2 
3. Asthma 
4. Hyperlipidaemia 
5. Rheumatoid Arthritis 




2.4 Inclusion criteria 
Only data pertaining to adults were collected and only medicines administered orally 
included in the study i.e., persons older than the age of eighteen years. 
 
2.5 Exclusion criteria 
Combination drugs (e.g., a combination of an oral blood glucose lowering drug, metformin 
and sulphonylurea) often, but not invariably, do not have a specified DDD and were 
therefore excluded.  
 
2.6 Analysis 
Data were captured into a spread sheet for analysis. Once entered into a spread sheet, 
pricing differences, means, standard deviation and percentage differences were calculated. 
Representational graphs were thereafter generated to explicate the results of the study. All 
pricing captured are SEPs inclusive of VAT, but excluding dispensing fees, in South African 
Rand value.  
 
2.7  Ethical considerations 
Since all data utilised in this study was available in the public domain, it was not necessary 
to obtain ethics approval. However, the protocol was given full ethics “exemption” by the 
Biomedical Research Ethics Committee, University of KwaZulu-Natal, South Africa (BREC 
Ref.: EXM 295/14) (Appendix B). Informed consent was not required for this study, since no 
subjects, persons or medical records were utilized. The research was conducted with 
honesty and the work of other authors, used in this study, was fully acknowledged. 
  





CHAPTER 3: RESULTS 
 
3.1 Introduction 
In this chapter, the data are analysed and discussed with reference to the aim and 
objectives of the study.  
 
3.2  Antihypertensive medicines 
For the treatment of hypertension, 12 active ingredients identified were: 
hydrochlorothiazide; furosemide; spironolactone; enalapril; perindopril; ramipril; captopril; 
amlodipine; methyldopa; atenolol; bisoprolol and propranolol.  
 
As shown in Figure 1, there was 49.68% difference in cost for hydrochlorothiazide 25mg 
between the innovator and the cheapest generic drug price. In the case of furosemide in 
2014, there was a major price difference of 97.14% (R132.25) between the innovator and 
the cheapest generic. The difference between the mean generic price and cheapest generic 
price is 66.29% (R7.67). It would work out much more cost effective if a patient were to 
receive a 120,  25mg spironolactone tablets instead of 30, 100mg spironolactone tablets (a 
saving of R83.46 as seen with the cheapest generic). With other diuretics, there was a 
difference of 4.45% (R1.58) between the spironolactone 25mg innovator and cheapest 
generic.  
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For enalapril, a similar pattern of price differences is seen amongst all the strengths as 
shown in Figure 2, except for the enalapril 10mg, in which there was only 4.1% (R1.90) 
difference between the innovator and mean generic price. As for ramipril 5mg, a price 
difference of 65.48% (R195.15) existed between the innovator and cheapest generic, and 
50.97% (R151.90) between the innovator and the mean generic price. This means that a 
patient could purchase almost 3 months’ supply of the cheapest generic of ramipril 5mg for 
the price of one month’s supply of ramipril innovator. The captopril 25mg had a difference 
of 92.17% (R156.16) between the innovator and cheapest generic, and 80.37% (R136.16) 
between the innovator and mean generic price. 
 
Figure 2: Prices of antihypertention medication – ACE inhibitors in 2014. 
 





There was a trend of saving for the two strengths of the amlodipine range from the use of 
generic medicines. A saving of 78.51% (R129.09) between the innovator and cheapest 
generic, and 58.52% (R96.23) between the innovator and mean generic price was seen for 
amlodipine 5mg, and 48.18% (R32.86) between the mean and cheapest generic. The 
amlodipine 10mg has a saving of 72.16% (R162.50) between the innovator and cheapest 
generic, and 40.65% (R42.94) between the mean generic and cheapest generic price. 
Methyldopa has a saving of 42.95% (R14.16) between the innovator and cheapest generic as 
seen in Figure 3, below. 
 

























































As shown in Figure 4, there were more considerable savings from the use of generic beta-
blockers in the treatment of hypertension. The atenolol 50mg had a saving of 90.74% 
(R158.44) between the innovator and cheapest generic, 86.72% (R151.43) between the 
innovator and mean generic price, and 30.24% (R7.01) between the mean generic price and 
the cheapest generic. For atenolol 100mg, a saving of 90.28% (R256.31) between the 
innovator and cheapest generic, 86.20% (R244.78) between the innovator and mean 
generic, and 29.47% (R11.53) between the mean generic and cheapest generic. The 
bisoprolol 5mg and 10mg had a saving of 54.21% (R53.37) and 51.27% (R79.82) between the 
innovator and cheapest generic respectively. Propranolol had a similar savings potential of 
94.81% (R45.29) and 96.40% (R115.26) for the 10mg and 40mg tablets respectively.  
 








































































3.3 Diabetes Mellitus Type 2 medicines 
The oral antidiabetic medicines included in this study belonged to two pharmacological 
classes - that is, the biguanides and sulphonylureas. A total of four active ingredients were 
identified - i.e. metformin; glibenclamide; gliclazide and glimepiride.      
 
As shown in Figure 5, there was a noticeable trend in the metformin price among the two 
strengths. A saving of 39.66% (R6.52) existed between the innovator and the cheapest 
generic, 30.90% (R5.08) between the innovator and the mean generic price, and 12.68% 
(R1.44) between the mean generic and cheapest generic for a month’s supply of metformin 
500mg. For metformin 850mg, a saving of 38.21% (R11.21) between the innovator and 
cheapest generic, 29.62% (R8.69) between the innovator and mean generic, and 12.20% 
(R2.52) between the mean generic and cheapest generic existed.  
 




































































Glibenclamide had the largest variation in price when compared with the available brands as 
seen in Figure 6. A saving of 95.70% (R153.11) existed between the innovator and cheapest 
generic, 95.46% (R152.73) between the innovator and mean generic, and 5.23% (R0.38) 
between the mean generic and cheapest generic. The innovator had therefore priced itself 
significantly higher than all available generic brands, and will most likely have the least 
market share. The gliclazide 80mg had a saving of 57.94% (R25.65) between the innovator 
and cheapest generic, glimepiride 1mg and 2mg have a saving of 53.79% and 51.87% 
between the innovator and cheapest generic respectively.    
 

































































3.4 Asthma medicines 
Asthma medicines included in this study consisted of 3 pharmacological classes and four 
active ingredients, i.e., salbutamol; theophylline; budesonide and beclomethasone were 
available for analysis.  
 
As shown in Figure 7, a salbutamol 100µg 200 dose unit had a saving of 65.39% (R42.63) 
between the innovator and cheapest generic, 45.21% (R29.47) between the innovator and 
mean generic, and 36.84% (R13.16) between the mean generic and cheapest generic. 
Theophylline had a single generic drug for each strength of the active ingredient available. 
There was a saving of 70.95% (R107.38) and 63.36% (R111.23) for the 200mg and 300mg 
respectively.     
 





Figure 7: Prices of asthma medication in 2014. 
 
The cheapest generic for budesonide 100mg costs 23.79% (R45.51) less than the innovator 
(Figure 8). The innovator of budesonide 200µg is 14.68% (R32.90) cheaper than the mean 
generic price and 8.06% (R16.76) cheaper than the cheapest generic. More importantly, it is 
noted that the innovator of budesonide 100µ and 200µ was the same price. The 
beclomethasone 100µg has a saving of 61.49% (R126.49) between the innovator and 
















































































































3.5 Hyperlipidaemia medicines 
 One class of hyperlipidaemia medicines was identified, i.e., the HMG-CoA reductase 
inhibitors and the following active ingredients were available for analysis; simvastatin; 
atorvastatin and pravastatin.   
 
The entire statin range had a similar pattern of price distribution, with the mean generic and 
cheapest generic having a minimum of 39% cheaper price than the innovator (refer to 
Figure 9). The simvastatin 10mg had a price difference of 77.70% (R75.69) between the 
innovator and cheapest generic. The simvastatin 20mg had a price difference of 79.76% 
(R88.80) between the innovator and cheapest generic. The atorvastatin 10mg had a saving 
of 85.29% (168.78) between the innovator and cheapest generic, and 33% (14.33) between 
the mean generic and cheapest generic. And the pravastatin 10mg has a saving of 43.96% 
(R100.78) between the innovator and cheapest generic. 































































HMG-CoA Reductase Inhibitors used in the  









3.6 Anti-rheumatic medicines 
Anti-rheumatic medicines included in this study were from five different pharmacological 
classes of drugs, i.e., the disease-modifying anti-rheumatic drugs, corticosteroids, non-
steroidal anti-inflammatory drugs (NSAIDs) and the anilide. The active ingredients identified 
were: chloroquine, methotrexate; prednisone; ibuprofen; diclofenac; naproxen and 
paracetamol.     
 
As shown in Figure 10, chloroquine had a saving of 54.61% (R38.58) between the innovator 
and cheapest generic. Methotrexate had a saving of 25.98% (R13.00) between the innovator 
and cheapest generic, and 2.83% (R1.08) between the mean generic and cheapest generic 
price. Prednisone had a saving of 97.11% (R112.37) between the innovator and cheapest 
generic, and 97.06% (R112.31) between the innovator and mean generic. It is was 
interesting to find that prednisone had three different generic brands available in South 
Africa with an average price of R3.40 per month, which was substantially cheaper than the 





































































Disease-modifying anti-rheumatic drugs used in the  









As shown in Figure 11, it is clear that there is great potential savings from the use of generic 
medicines. For example, the ibuprofen 400mg had a saving of 90.36% (R35.70) between the 
innovator and cheapest generic, the diclofenac 25mg had 89.36% (R21.33), the diclofenac 
50mg had 93.33% (R45.31), the naproxen 250mg had 77.29% (R28.99) and the paracetamol 
500mg had 69.89% (R7.52) savings. More importantly, the paracetamol 500mg generic 
brands had similar prices.    
 

































































Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Paracetamol used 









3.7 Cross-sectional treatment cost comparison for September 2006 and July 2014   
Figure 12, shows that all innovator medicine prices have increased, with the greatest 
increase being that of the captopril 25mg at 71.92% (R121.87). Interestingly, it was also 
discovered that hydrochlorothiazide 25mg did not have a generic alternative in 2006 and 
the amlodipine 5mg was the only antihypertensive drug to have had a price decrease (of 
54.26% or R41.92) between 2006 and 2014.        
 
 
Figure 12: Cross-sectional treatment cost comparison for antihypertensives 
 
A similar trend of price increase was seen with the oral anti-diabetes medicines (refer to 
Figure 13). There was a huge increase in the innovator price for glibenclamide 5mg 
(35.80%), and with gliclazide 80mg there was a 17.08% increase – while the metformin 































































The cheapest generic for glibenclamide 5mg, had the greatest price increase of 28.05% 
between 2006 and 2014  






























































All the active ingredients for the management of asthma, as depicted in Figure 14 have a 
similar trend, showing an increase in all drug prices. However, the innovator of salbutamol 
100µg had the lowest price increase of 21.15%, while budesonide 100µg had the highest 
with 39.25% over the studied period as seen in Figure 14. Interestingly, the innovator and 
cheapest generic of theophylline 200mg had increased by 33% over the comparison period.    
 
































































Remarkably, as seen in Figure 15, the price of simvastatin for both the 10mg and 20mg of 
the innovator and cheapest generic has decreased remarkably over the comparison period. 
The innovator brands of simvastatin 10 and 20mg had decreased by 25.44% and 32.83%, 
while the cheapest generics had plummeted by 69.95% and 72.32% respectively. Also of 
note is that in 2006, atorvastatin did not have a generic alternative.     
 






























































Cost comparison for HMG-CoA Reductase Inhibitors in  











In Figure 16 it is seen that large price increases have occurred over the evaluation period. Of 
all the innovator medicines, prednisone 5mg had the greatest increase (35.67%). 
Methotrexate 2.5mg cheapest generic had the biggest price upsurge of 75.70%.     
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Cost comparison for Anti-rheumatic Medicines  in  










CHAPTER 4: DISCUSSION  
 
4.1  Introduction 
This study quantitatively assessed the potential saving from the use of generic medicines for 
the treatment of the most common non-communicable diseases among adults in South 
Africa. The main objective of this study was to determine if there was a cost saving by using 
generic medicines for the treatment of each chronic disease based on the single exit price 
and the monthly defined daily dosage. The saving potential was constructed around the 
innovator price, the mean generic price and the cheapest generic price. The second 
objective was to compare the current drug prices with data from eight years ago.  
 
Forty three drugs were investigated, forty one (95.3%) were found to have a cheaper 
generic alternative available. One (2.3%) generic drug was the same price as the innovator, 
and one (2.3%) innovator drug was cheaper than the generic. These results further illustrate 
the advantages of generic substitution as Shrank and partners (2011a) reported that generic 
medicines are cost-effective and can save lives by increasing the affordability and 
accessibility of quality healthcare to the population.        
 
4.2 Cost Savings When Generic Medicines are used to treat Hypertension 
This study has shown that, with regards to diuretics, there was about 50% and 97% savings 
for hydrochlorothiazide and furosemide respectively when generic medicines are utilised to 
treat hypertension instead of innovator products. This is in line with Farfan-Portet and 
colleagues (2012) who found that there is a price difference of €2.47 for furosemide, based 
on the generic price reference system of Belgium, also, they mentioned that patients 





registered with a PHC centre had a better chance of receiving generic alternatives due to 
good prescribing habits (Farfan-Portet et al., 2012).  Interestingly, if a patient was to be 
treated with a dosage of spironolactone 100mg, it would compute 38% cheaper to purchase 
a hundred and twenty of the 25mg generic tablets rather than the thirty of the 100mg, but 
patient adherence to treatment may thereafter become a factor.  
 
Concurring with our findings, García and partners (2004) reported that the use of generic 
drugs reduced the expenditure on ACE inhibitors by almost 7% even though the sales had 
increased by approximately 18% (García et al., 2004). In this study there was a potential 
savings of 44%, 30% and 62% for each of the 5mg, 10mg and 20mg tablets, respectively, for 
enalapril. Another ACE inhibitor, ramipril, had a saving of 65% between the innovator and 
cheapest generic drug price. However, captopril had an even greater price difference of 
92%. This is in line with findings from Nicolosi and Gray (2009), who reported a saving of 
42% for ramipril and 86% for captopril.  
  
In the case of amlodipine 5mg a saving of 59% was seen in our study, and this was in line 
with the findings of Olusola et al. (2012), who investigated the equivalence of two generic 
brands of amlodipine and found a 65% price difference between the innovator and cheapest 
generic alternative. Unfortunately, Federman and partners (2006) reported that patients 
diagnosed with hypertension do not fully utilise generic medicines, seen with 3 of the 5 
cardiovascular pharmacological drug classifications, and therefore they are not enjoying the 
benefits associated with generic medicines of which out-of-pocket costs is a major 
advantage (Federman et al., 2006).  
  





4.3 Cost Savings When Generic Medicines are used to treat Diabetes Mellitus Type 2 
With regards to the biguanides, a saving of approximately 38% to 39% was seen for both 
strengths of metformin. In the category of sulphonylureas, glibenclamide had a substantial 
saving of 96% when generic medicine were used, while gliclazide came in second with a 
saving of 58%, however in Poland a saving of only 4% was found for gliclazide, but this 
marginal difference is most probably due to the Polish generic market element, which is 
driven by supply measures (Simoens, 2009).   
 
Interestingly glimepiride had an average difference of 52% between the innovator and 
generic brand.  With the promising saving from the use of generic medicines for the 
treatment of type 2 diabetes, the switch from innovator to generic medicines may 
contribute to better treatment adherence due to fewer out-of-pocket costs as seen with 
innovator medicines (Piette et al., 2004).   
 
4.4 Cost Savings When Generic Medicines are used to treat Asthma 
The potential saving from the use of generic medicine for the management of asthma varied 
widely for each active ingredient. The major saving was that of theophylline, 71% (200mg) 
and 63% (300mg) respectively. Salbutamol is often used as a bronchospasm reliever for 
many asthma sufferers, the generic alternative costs 65% less than the innovator, 
nonetheless this finding is seen in relation to Ghanname et al., (2014), who reported that 
even though the innovator price is aligned with its international price, and the generic costs 
29% less in Morocco, the sales of the innovator remain higher than the generic due to poor 
prescribing habits.  
 





Unexpectedly the innovator of budesonide 200µg, costs 15% less than the mean generic 
price and 8% lower than the cheapest generic. Also, in this study it was discovered that 
budesonide 100µg and 200µg cost the same. The reason for this is unknown, but a possible 
explanation is that the innovator is attempting to gain market share to improve sales 
turnover. In Poland, a saving of 61% was seen from the use of a generic budesonide inhaler, 
whereas in this study a saving of 24% was calculated for the budesonide 100µg (Simoens, 
2009).          
 
4.5 Cost Savings When Generic Medicines are used to treat Hyperlipidaemia  
In this study we have shown that the pattern of prices of statin drugs were similar. The 
standout drug is atorvastatin of which there was an 85% saving from the use of generic 
medicine. Simvastatin had an average saving of 78%, while the pravastatin generic saved the 
consumer 44%. In this regard, our findings were in line with those of Cullen et al., (2014), 
who reported that generic statins have a lower cost, similar effectiveness and would 
support the health system by lowering overall medicines costs.  
 
The lower cost of drugs from the use of generic medicines has advantages of better 
adherence, and fewer therapy discontinuations, as Casula and team (2012), had discovered 
that patients fail to comply due to multiple factors, but most importantly out-of-pocket cost 
was a key aspect (Casula et al., 2012). Similar results were also seen in a study conducted in 
Europe (Godman et al., 2010) where the healthcare system was capable of providing quality 
healthcare with minimal resources propelled by the utilisation of generic medicines.      
 
 





4.6 Cost Savings When Generic Medicines are used to treat Rheumatoid Arthritis  
The management of rheumatoid arthritis consisted of two categories of drugs, the disease-
modifying anti-rheumatic drugs and non-steroidal anti-inflammatories. Of all the drugs 
investigated in this study for the treatment of rheumatoid arthritis, the generic alternative 
was found to be cheaper than the innovator.  
 
Prednisone remarkably, had a price difference of 97.1% when the innovator was compared 
to the cheapest generic. This was a substantial saving of note although prednisone has 3 
generic alternatives, the innovator price is significantly higher, as seen by a price difference 
97% between the innovator and mean generic price. This will be of great advantage for 
patients that used prednisone for conditions other the rheumatoid arthritis. In Canada, 
similar results were shown whereby generic substitution of NSAIDs produced approximately 
$1 million (CAN) in annual savings (Grootendorst, 2005).        
 
4.7  Changes of prices of medication over time  
Over a period of eight years, nominated innovator and generic drug prices were formulated 
for a comparison. An overview of the results in this study acclimate the drug price increase 
to that in line with the average inflation rate of South Africa for most medicines.        
 
In the treatment of hypertension, major price increases were seen for amlodipine, captopril 
and atenolol. The amlodipine innovator had a price increase 36% over the period of 8 years, 
surprisingly the generic price had decreased by 54% over the same period, however, a 
possible reason for this decrease in 2014, is in 2006 only one alternative generic for 
amlodipine was available on the market. These findings are dissimilar to that of a study 





conducted by Wenjie in China, where the price of generic amlodipine had increased 
between 2006 and 2011, although the usage had increase by 6 folds (Wenjie, 2013).  The 
captopril innovator had a price increase of 72% which is aligned with Alpern and colleagues 
(2014) in which they found that the price of captopril increased by 2800% over a period of 2 
years in the US, this however is substantially higher than the price increase seen in South 
Africa. 
 
For the treatment of diabetes type 2, the highest possible increase was seen in 
glibenclamide 36%, however the generic price remained fairly low in comparison to the 
innovator over the period of 8 years. The metformin generic price appeared to have 
stabilised with a minimal increase over the 8 year period and well within inflation rates. In 
the management of asthma, all medicine prices had increased over the 8 year period and 
percentile increase seemed to be within inflation rates.  
 
The innovator of simvastatin had a price decrease over the 8 year period, this is possibly due 
to the patent expiry and arrival of many new generic alternatives. More importantly, the 
generic prices of simvastatin have decreased over time, which is due to tough competition 
for market share in the healthcare environment. Also, in 2006, atorvastatin did not have a 
generic available due to the patent protection, currently there are generic alternatives 
available with the cheapest one being 85% cheaper than the innovator. In China, the price 
of generic atorvastatin had decreased between 2006 and 2011 although the usage increased 
(Wenjie, 2013) 
 





In the treatment of rheumatoid arthritis, there has been a significant increase in the price of 
the generic methotrexate (76%). Ibuprofen and diclofenac generics have had smaller price 
increases which are within inflation rates.   
 
The findings of this study are in line with Huckfeldt and Knittel (2011) who reported that an 
innovator usage declines promptly upon the release of a generic product. In another study 
conducted by Wenjie (2013) in China, between 2006 and 2011, the market share was 
dominated by innovator drugs based on volume and monetary value.     
         
4.8 Limitations 
An important limitation to the study is that only medicines recorded in the Pharmaceutical 
Blue Book were studied. It is possible that there were more generic alternatives available on 






CHAPTER 5: CONCLUSION AND RECOMMENDATIONS 
 
This study assessed the potential savings from the use of generic medicines for the 
treatment of five of the most common non-communicable diseases in adults in South Africa. 
The main objective of the study was to determine the cost differential between innovator 
and generic medicines used in the treatment of the most common NCDs and to compare 
the price differential between generic and innovator medicines in 2006 and 2014. The cost 
saving was calculated based on the SEP and DDD of each drug.  
 
The SEP was introduced into South Africa in 2004, after plentiful criticism from the 
pharmaceutical industry to overrule its instatement. The SEP structure lists the maximum 
price that a medicine can be charged for taking into consideration the fixed dispensing fee 
added to the mark-up charged on the SEP. In South Africa, the private sector provides 
healthcare for approximately 8 million citizens most of whom belong to a medical scheme, 
while the government manages the other 42 million residents that are unable to afford 
private healthcare (Gray, 2014). Therefore the government needs to review its procurement 
procedure by suggesting a tender renewal every 6 months for all drugs supplied in the state 
sector. This outcome would yield greater competition among local drug manufacturers and 
moreover provide an enticement for international pharmaceutical companies who could 
also supply the local market which is also known as parallel importation.   
 
The public’s perception towards generic medicine needs to be changed, most patients 
believe that generic medicines do not work as well as their innovator counterparts. This 





level just prior to entering the tertiary world as they would soon be purchasing their own 
medicine. Furthermore, drug advertising, and generic substitution should be introduced to 
undergraduate healthcare students as it would be the perfect period to instil the positives 
of generic medicines in the future leaders of society and the healthcare fraternity.  
 
Generic substitution needs to be perpetuated in all healthcare sectors, the benefits clearly 
overshadow the controversial speculations that are made by certain persons. A generic drug 
is made of the same active ingredient as the innovator and the bioequivalence is expected 
to be of similar standards. The use of generic medicines is therefore encouraged to allow for 
greater access and affordability of quality healthcare.  
 
Pharmacists play a crucial role in driving the generic substitution mandate and it is therefore 
vital that each and every one helps to maintain and promote this advantageous model. The 
prescribing patterns of medical practitioners need to change, as their prescribing trends are 
quite often influenced by sales representatives and outdated research. Prescribers need to 
revitalise their methods of prescribing and where possible adjust their attitude towards 
generic medicines as it is here to stay.            
 
In this study it has shown that there is a significant saving potential from the use of generic 
medicines over innovator medicines for the treatment of the most common non-
communicable diseases in adults in South Africa. This has been proven by comparing the 
single exit price of innovator medicines against that of generic alternatives. Secondly, this 





in line or below, with the countries inflation rate, and some generic medicine prices had 
actually decreased over time.  
 
It is recommended that further research be undertaken to assess disease specific cost saving 
potential from the use of generic medicines instead of innovator medicines, and how the 
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Appendix A – 48: Data capture sheet - Hypertension 
Disease Class of drug Active Ingredient Brands 
 
Cost (ZAR) 





Hypertension Diuretics Hydrochlorothiazide 25mg Ridaq 24.68     
      Hexazide     12.26 
    
     
    Furosemide 40mg Austell Furosemide 20.86     




      Dino-Retic 5.18 
  
      Lasix 136.15 
  
      Mylan Furosemide 
  
3.90 
      Puresis 19.00 
  
      Sandoz Furosemide 15.93     
    
     
    Spironolactone 25mg Aldactone   35.49   




      Sandoz Spironolactone 
  
33.94 
      Spiractin 35.52     
    Spironolactone 100mg Aldactone 219.22 
  
      Spiractin 219.22     
  
      
 
ACE Inhibitors Enalapril 5mg Alapren     18.76 
 
    Ciplatec 29.65 
  
 





    HR-Enalapril 30.00 
  
 
    Pharmapress 29.54 
  
      Renitec 33.22     
    Enalapril 10mg Adco-Enalapril 62.19     
 








    Ciplatec 43.78 
  
 
    Enap 42.20 
  
 









      Renitec 46.00     
    Enalapril 20mg Adco-Enalapril 129.04     
 




    Ciplatec 74.21 
  
 
    Enap 74.11 
  
 





    Pharmapress 74.76 
  
 
    Renitec 84.20 
  
              
 
  Perindopril 4mg Auro-Perindopril 80.38     
 
    Ciplasyl 81.05 
  
 
    Coversyl 136.74 
  
 
    Pearinda 81.11 
  
 
    Prexum 103.32 
  
 




    Spec-Perindopril 80.01 
  
 
    Vectoryl 81.12 
  
      Zydus-Perindopril   76.60   
 
  Ramipril 5mg Adco-Rilace     102.87 
 





    Austell Ramipril 140.05 
  
 
    Ramace 224.14 
  
 
    Ramipril Hexal 143.06 
  
 
    Ramiwin 143.00 
  
 







    Retace 143.06 
  
      Tritace 298.02     
       
 
Calcium channel blockers Amlodipine 5mg Almadin 65.00     
 
    Amloc 77.17 
  
 
    Amlodac 61.59 
  
 
    Amlosyn 120.34 
  
 
    Austell Amlodipine 65.99 
  
 
    Calbloc 63.84 
  
 
    Ciplavasc 65.77 
  
 









    Keysal 69.30 
  
 
    Lomanor 61.50 
  
 
    Norcard 70.90 
  
 
    Norvasc 160.43 
  
 
    Pendine 65.16 
  
      Sandoz Amlodipine 74.29     
 
  Amlodipine 10mg Almadin 101.21     
 
    Amloc 114.62 
  
 
    Amlodac 99.99 
  
 
    Amlosyn 168.94 
  
 
    Austell Amlodipine 100.00 
  
 
    Calbloc 96.44 
  
 
    Ciplavasc 106.46 
  
 




    Keysal 107.97 
  
 












    Norvasc 225.20 
  
 
    Pendine 103.28 
  
      Sandoz Amlodipine 115.82     
       
 
Beta-adrenergic blockers Atenolol 50mg Adco-Atenolol 35.85     
 
    Bio-Atenolol 16.50 
  
 





    Hexa-blok 24.50 
  
 
    Sandoz Atenolol 19.52 
  
 
    Ten-bloka 37.92 
  
 
    Tenopress 18.51 
  
 
    Tenormin 174.61 
  
      Zetenol     16.17 
 
  Atenolol 100mg Adco-Atenolol 52.47     
 
    Bio-Atenolol 28.68 
  
 





    Hexa-blok 49.01 
  
 
    Sandoz Atenolol 37.26 
  
 
    Ten-bloka 55.54 
  
 
    Tenopress 34.46 
  
 
    Tenormin 283.91 
  
      Zetenol     27.60 
 
  
     
 
  Bisoprolol 5mg Adco-Bisocor     45.08 
 
    Betacor 50.78 
  
 
    Bilocor 50.79 
  
 
    Bislo 51.86 
  
 
    Bisoprolol Hexal 55.40 
  
 







    Bisohexal 47.62 
  
 
    Cardicor 98.45 
  
 
    Concor 98.45 
  
      Ziapro   47.58   
 
  Bisoprolol 10mg Adco-Bisocor     75.86 
 
    Betacor 85.34 
  
 
    Bilocor 85.40 
  
 
    Bislo 87.84 
  
 
    Bisoprolol Hexal 93.47 
  
 
    Bisoprolol Unicorn 85.42 
  
 
    Bisohexal 80.31 
  
 
    Cardicor 155.68 
  
 
    Concor 155.68 
  
      Ziapro   80.28   
 
  
     
 
  Propranolol 10mg Inderal 47.77     
 









    Pur-Bloka 4.81 
  
      Sandoz Propranolol 3.61     
 
  Propranolol 40mg Inderal 119.57     
 




    Prodolol 5.86 
  
 
    Pur-Bloka 6.35 
  
      Sandoz Propranolol   4.79   
       
 
Centrally acting agents Methyldopa Hy-Po-Tone 24.84     
 





















      Sandoz-Methyldopa     18.81 
       
  
Captopril  25mg Adco-Captomax 16.86 
  
   
Adco-Captopril 18.13 
  
   
Bio-Captopril 17.64 
  
   
Capace 74.07 
  
   
Capoten 169.42 
  
   
Captohexal 32.68 
  
   
Cardiace 94.62 
  









   
Sandoz Captopril 24.95 
  







Appendix A – 49: Data capture sheet – Diabetes Mellitus Type 2 
Brands Cost (ZAR) 
  Most Expensive (X) 
2nd Least Expensive 
(Y) Least Expensive (Z) Difference 
Accord Metformin 10.29       
Apex Metformin 11.82 
  
  
Arrow Metformin 11.39 
  
  




















Indo Metformin 10.72 
  
  















Metored FC 11.41 
  
  
Mylan Metformin 11.14 
  
  
Sandoz Metformin 11.54       




Apex Metformin 21.57 
  
  
Arrow Metformin 21.28 
  
  





















































Mylan Metformin 19.85 
  
  
Sandoz Metformin 24.12       















          
Adco Glucomed   23.95   20.32 
Alembic Gliclazide 26.51 
  
  






















Mylan Gliclazide 26.72 
  
  
Sandoz Gliclazine     18.62 25.65 




Aspen Glimepiride 54.89 
  
  





























Zydus Glimepiride 63.85       
     Accord Glimepiride     86.05 92.75 
Amaryl  178.80 
  
  
Aspen Glimepiride 107.49 
  
  






















































Appendix A – 50: Data capture sheet - Asthma 
Active Ingredient Brands Cost (ZAR) 
    Most Expensive (X) 
2nd Least Expensive 
(Y) Least Expensive (Z) 
Salbutamol 100µg Asthavent 200 Dose     22.56 
  Airomir 200 Dose 65.19 
    Venteze 200 Dose 
 
24.74 
   Ventolin 59.87     
     Budesonide 100µg Budeflam     145.75 
  Inflammide 
 
170.56 
 innovator Pulmicort 191.26 
            
Budesonide 200µg Budeflam 
 
208.02 
   Inflammide 240.30 
  innovator Pulmicort     191.26 
     Beclomethasone 100µg Beclate   127.21   
  Becotide 
  
79.21 
  Qvar  205.70     
     Theophyllin 200mg Sandoz Theophyllin      43.96 
  Theoplus 151.34     
     Theophyllin 300mg Sandoz Theophyllin     64.33 







Appendix A – 51: Data capture sheet – Hyperlipidemia  
Active Ingredient Brands Cost (ZAR) 
    Most Expensive (X) 2nd Least Expensive (Y) Least Expensive (Z) 
Simvastatin 10mg Adco-Simvastatin 32.38     
  Arrow Simvastatin 
 
28.29 
   Aspen Simvastatin 36.82 
    Austell Simvastatin 
  
21.72 
  Biovac Simvastatin 30.30 
    Cipla Simvastatin 29.91 
    Michol 36.87 
    Redicor 32.40 
    Simayla Simvastatin 34.31 
    Simcard 85.92 
    Simvacor 34.25 
    Simvotin 34.37 
    Simzor 32.40 
    Upidex 97.41 
    Zocor 76.92 
    Zysim 28.59     
     Simvastatin 20mg Adco-Simvastatin 32.38     
  Arrow Simvastatin 31.75 
    Aspen Simvastatin 36.82 
    Austell Simvastatin 
  
22.53 
  Biovac Simvastatin 35.98 
    Cipla Simvastatin 32.38 
    Michol 51.64 
    Redicor 32.40 






  Simcard 110.94 
    Simvacor 34.25 
    Simvotin 34.37 
    Simzor 32.40 
    Upidex 111.33 
    Zocor 76.92 
    Zysim   28.59   
     Atorvastatin 10mg Adco-Atorvastatin 32.10     
  Aspavor 32.10 
    Atolip 33.97 
    Atorvastatin Winthrop 70.44 
    Atorvastatin Unicorn 31.92 
    Dynator 
 
30.80 
   Lestavor 33.97 
    Lipitor 197.88 
    Lipogen 67.99 
    Ran-Atorvastatin 71.95 
    Vastor     29.10 
     Pravastatin 10mg Aspen Pravastatin 157.14     
  Austell Pravastatin 
 
131.15 
   Colite 140.48 
    Pixeta 132.22 
    Pranalip 
  
128.46 
  Prava 229.24 
    Sandoz Pravastatin 148.99     
 





Appendix A – 52: Data capture sheet – Rheumatoid Arthritis 
Active Ingredient Brands Cost (ZAR) 
  
Most Expensive (X) 2nd Least Expensive (Y) Least Expensive (Z) 
Chloroquine 150mg Daramal     32.07 
  Nivaquine 70.65 
    Plasmaquine   41.48   
     Methotrexate 2.5mg Abitrexate   39.18   
  Emthexate 
  
37.03 
  Methotrexate Pfizer 50.03 
  








  Trolic     3.34 


























JP Paracetamol 2.33 
  
 



































Von Paracetamol 2.46 
    Zydus Paracetamol     1.02 
     Ibuprofen 400mg Adco-Ibuprofen 7.75     
  Betaprofen 
 
4.00 
   Bren 4.15 
    Ibucine 4.26 
    Ibumax 
  
3.81 
  Inza 5.37 
    Nurofen Period Pain 39.51 
    Ranfen 4.68 
    Sandoz Ibuprofen 7.85     
     Diclofenac 25 mg Adco-Diclofenac 4.00     
  A-Lennon Diclofenac 
 
2.88 
   Diclohexal 25T 3.68 
    Diclofenac Biotech 
  
2.54 
  Mylan Diclofenac 2.61 
    Panamor  16.34 
    Sandoz Diclofenac 3.00 
    Voltaren 23.87     





Diclofenac 50mg Adco-Diclofenac 8.02     
  A-Lennon Diclofenac 
 
4.11 
   Diclohexal 12.94 
    Mylan Diclofenac 
  
3.24 
  Panamor AT 6.93 
    Sandoz Diclofenac 14.04 
    Voltaren GT 48.55     
     Naproxen 250ng Adco-Naproxen 33.40     
  Be-Tabs Naproxen 
  
8.52 
  Bio-Naproxen 17.15 
 
  
  Mylan Naproxen 13.05 
    Nafasol EC 37.51 
    Napflam 18.30 
    Naproscript 
 
10.40 
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